Roseburia

Roseburia is one of the groups of gut bacteria that make butyrate. Your colon lining uses butyrate for fuel. Stool studies have found differences in Roseburia abundance in inflammatory bowel disease, colorectal cancer, diabetes, and several other conditions, but these associations don't establish what an individual result means for your health.

Its use as a health marker remains exploratory. There are no established clinical targets, and a low result doesn't identify a disease or prove that you're eating too little fiber. Testing can describe part of your gut bacterial community, but using this result to choose treatment or predict future illness hasn't been validated.

What the Stool Result Measures

The result estimates Roseburia abundance from bacterial DNA in stool. Roseburia is a genus, a group of closely related species. It includes R. intestinalis, R. hominis, and R. inulinivorans. These bacteria grow in the colon's oxygen-poor environment, but the species differ in the carbohydrates they can use.

This genus-level result combines those species. A study of R. hominis alone therefore provides evidence about one member of the group, which may change differently from the genus as a whole. Stool also samples a different bacterial community from the organisms attached to the gut lining.

Abundance and activity are different measurements. A DNA result doesn't show how much butyrate these bacteria are making. Even a separate stool butyrate measurement captures what remains after production and absorption, with stool water content and transit time also affecting the concentration.

Cell and animal experiments suggest that butyrate can support the intestinal barrier and influence immune responses that limit inflammation. Those mechanisms help explain interest in Roseburia, but they don't establish that raising your stool result will repair the gut lining or improve a disease.

Ulcerative Colitis and Crohn's Disease

Some of the clearest human evidence concerns individual species. In a study of ulcerative colitis, stool R. hominis was lower than in healthy controls and fell as disease activity increased. A small study of untreated Crohn's disease found less R. intestinalis. Neither species measurement is identical to total Roseburia, and findings for the whole genus have varied between studies.

Genetic susceptibility may also matter. In a study that included 895 people with and without inflammatory bowel disease, healthy participants with a higher score for selected inherited risk variants had less Roseburia. This was a comparison at one point in time. It didn't show that those participants later developed bowel disease or that testing Roseburia could predict who would.

Researchers have also developed diagnostic combinations of several bacterial species. A study spanning nearly 6,000 stool samples evaluated a ten-species ulcerative colitis panel. In a targeted DNA-assay cohort, the panel separated most people with ulcerative colitis from controls. It also performed better than fecal calprotectin in some study comparisons, including inactive disease.

Those findings belong to the complete research panel and its analysis. They cannot be applied to an isolated Roseburia result. Fecal calprotectin measures an inflammatory response in the intestine; a bacterial profile describes which organisms are present. Differences between them don't establish that one can replace the other.

Colorectal and Stomach Cancer

Several colorectal cancer studies have found lower stool Roseburia or lower abundance of particular species, including R. intestinalis. In an exploratory study of 166 people with stage I to III colorectal cancer, higher Roseburia abundance was associated with longer disease-free survival after adjustment for clinical factors. This doesn't establish a target for cancer prevention or treatment.

In people already diagnosed with stomach cancer, lower stool Roseburia was associated with cancer spread within the abdomen. Its ability to distinguish those with and without that spread was modest. The study didn't test whether this measurement could screen healthy people for stomach cancer.

Research combinations of bacterial markers and tests for hidden blood have improved colorectal cancer detection in some studies. Those combinations contain several signals and use their own classification rules. An individual Roseburia result has no established role in colorectal cancer screening.

Stroke Recovery and Complications

Two hospital studies examined stool collected after an acute stroke caused by a blocked artery. Both found associations between Roseburia and subsequent outcomes.

These are observational findings. Stroke severity, swallowing problems, treatment, and changes in bowel function can accompany changes in gut bacteria. Because sampling happened after the stroke, the studies don't establish what the gut community was like beforehand or whether increasing Roseburia would improve recovery.

Blood Sugar, Weight, and Heart Health

Lower stool Roseburia has been reported in several studies of type 2 diabetes and coronary artery disease. A study of 1,914 adults also included Roseburia among bacterial features associated with obesity-related differences. These findings describe group patterns; they haven't established a way to estimate your glucose control or cardiovascular risk from this result.

The direction isn't uniform. In a pilot study of 44 adults, Roseburia was more abundant in groups with obesity, including those with and without persistently raised liver enzymes, than in lean participants with normal liver enzymes. The bacterial finding didn't reliably distinguish liver-enzyme abnormalities within the weight groups.

A separate study of 22 pregnant women with overweight or obesity found more Roseburia among those with ketones in their urine. Neither study established why the difference occurred. They don't support interpreting a high result as excess fermentation, liver injury, or a particular way of burning fuel.

Muscle Strength and Aging

A 2026 study found that higher stool R. inulinivorans abundance was associated with greater muscle strength, and that older adults carried less of this species than younger adults. The human findings were observational; the experimental evidence for a causal effect came from mice. Your genus-level result doesn't isolate R. inulinivorans or measure muscle function.

Other Conditions Studied

• Brain and nerves: Parkinson's disease studies have reported depletion of particular butyrate-producing species, including R. intestinalis. Some multiple sclerosis studies found lower Roseburia, but a larger analysis using absolute bacterial counts and accounting for stool moisture and other factors did not retain that association.
• Eating and digestion: lower Roseburia has been reported in anorexia nervosa. A small constipation study linked its abundance with stool butyrate and differences in colon transit.
• Kidneys: studies of chronic kidney disease have reported lower Roseburia, including differences associated with disease severity. This hasn't established a clinical kidney-function test.
• Pain and mood: lower genus-level abundance has been reported in chronic pain studies and in adolescents with depression. These associations don't establish that the bacterial difference caused the symptoms.

The appearance of similar bacterial changes across different illnesses limits their diagnostic specificity. Illness, diet, medicines, and bowel transit can all contribute. A shared association doesn't establish whether Roseburia is a cause, a consequence, or both.

When Results Can Be Misleading

• Different laboratory methods: DNA extraction, bacterial targets, sequencing methods, and analysis software affect the result. A study using identical stool material found substantial differences between testing services, with particularly poor agreement for Roseburia.
• Percentages versus counts: a bacterial percentage can fall because other bacteria increase, even if the amount of Roseburia stays the same. Percentages and estimated counts per gram cannot be compared as equivalent measurements.
• Stool transit and water content: slow transit, constipation, and watery stool can change both the bacterial community and the concentration measured in a sample. These factors can also explain some apparent disease associations.
• Recent changes in diet or medicines: diet, antibiotics, and other treatments can alter the bacterial community. A sample taken during a change may not represent your usual pattern.
• Genus versus species: two people with the same genus-level result can carry different species. Findings about one species don't automatically apply to the combined result.
• Collection and storage: contamination, preservation, transport time, and temperature can affect the DNA profile.

What a Change Over Time Means

Repeat measurements can describe changes in your stool bacterial community, especially when the same assay and collection conditions are used. A change can still reflect sampling variation or shifts in other bacteria. No validated amount of increase has been shown to mean that your gut barrier, metabolic health, or long-term disease risk has improved.